OliX Pharmaceuticals's clinical trial application for OLX10212, a treatment for age-related macular degeneration, was rejected in New Zealand for Phase 2a studies.

OliX Pharmaceuticals's clinical trial application for Phase 2a studies of OLX10212 in New Zealand was rejected by the Northern B New Zealand Health and Disability Ethics Committee. The reason for rejection was that the application did not meet New Zealand's ethical standards and applicable regulations. OliX Pharmaceuticals is carefully reviewing the issues raised and preparing for resubmission and reconsideration, and plans to proceed with the relevant procedures promptly.

1. 01

   The investigational new drug (IND) application for OLX10212 clinical trials by OliX Pharmaceuticals was rejected by the Northern B New Zealand Health and Disability Ethics Committee.

2. 02

   The reason for rejection was that the clinical trial application did not meet New Zealand's ethical standards and applicable regulations.

3. 03

   OliX Pharmaceuticals is reviewing the issues raised by the committee and preparing for resubmission and reconsideration.

An AI model translated the Korean summary of this filing into English; every number is carried over from the Korean original. Reference information, not investment advice.

Key figures

Target indication

Age-related macular degeneration (AMD) with bilateral geographic atrophy (GA)

Clinical trial phase

Phase 2a in New Zealand

Route of administration

Intravitreal injection

Reason for rejection

Non-compliance with the country's ethical standards and applicable regulations

Filing facts

Filing type

Technology or Regulatory Approval

Report name

Material Management Information for Investment Decisions

Filed

Oct 12, 2026

Receipt number

20261012900388